These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 2521352)
1. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. Levitz SM; DiBenedetto DJ J Immunol; 1989 Jan; 142(2):659-65. PubMed ID: 2521352 [TBL] [Abstract][Full Text] [Related]
2. Fungicidal activity of IFN-gamma-activated macrophages. Extracellular killing of Cryptococcus neoformans. Flesch IE; Schwamberger G; Kaufmann SH J Immunol; 1989 May; 142(9):3219-24. PubMed ID: 2496162 [TBL] [Abstract][Full Text] [Related]
3. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. Horwitz MA; Silverstein SC J Clin Invest; 1980 Jan; 65(1):82-94. PubMed ID: 6985617 [TBL] [Abstract][Full Text] [Related]
4. Killing of Cryptococcus neoformans by rat alveolar macrophages. Bolaños B; Mitchell TG J Med Vet Mycol; 1989; 27(4):219-28. PubMed ID: 2677299 [TBL] [Abstract][Full Text] [Related]
5. [The defensive role of human pulmonary alveolar macrophages and polymorphonuclear leukocytes against a strongly or weakly virulent strains of Cryptococcus neoformans]. Tabeta H; Kohno N; Kamei K; Honda A; Unno H; Nagao K; Yamaguchi T; Miyaji M Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Sep; 29(9):1174-9. PubMed ID: 1753544 [TBL] [Abstract][Full Text] [Related]
6. Phagocytosis of Cryptococcus neoformans by rat alveolar macrophages. Bolaños B; Mitchell TG J Med Vet Mycol; 1989; 27(4):203-17. PubMed ID: 2677298 [TBL] [Abstract][Full Text] [Related]
7. Differential binding of acapsulate and encapsulated strains of Cryptococcus neoformans to human neutrophils. Richardson MD; White LJ; McKay IC; Shankland GS J Med Vet Mycol; 1993; 31(3):189-99. PubMed ID: 8360810 [TBL] [Abstract][Full Text] [Related]
8. The efficacy of complement-mediated phagocytosis of Cryptococcus neoformans is dependent on the location of C3 in the polysaccharide capsule and involves both direct and indirect C3-mediated interactions. Zaragoza O; Taborda CP; Casadevall A Eur J Immunol; 2003 Jul; 33(7):1957-67. PubMed ID: 12884862 [TBL] [Abstract][Full Text] [Related]
9. Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. Levitz SM; Tabuni A J Clin Invest; 1991 Feb; 87(2):528-35. PubMed ID: 1991837 [TBL] [Abstract][Full Text] [Related]
10. Ingestion of acapsular Cryptococcus neoformans occurs via mannose and beta-glucan receptors, resulting in cytokine production and increased phagocytosis of the encapsulated form. Cross CE; Bancroft GJ Infect Immun; 1995 Jul; 63(7):2604-11. PubMed ID: 7790075 [TBL] [Abstract][Full Text] [Related]
11. Differential stimulation of murine resident peritoneal cells by selectively opsonized encapsulated and acapsular Cryptococcus neoformans. Levitz SM; DiBenedetto DJ Infect Immun; 1988 Oct; 56(10):2544-51. PubMed ID: 3138176 [TBL] [Abstract][Full Text] [Related]
12. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Rachini A; Pietrella D; Lupo P; Torosantucci A; Chiani P; Bromuro C; Proietti C; Bistoni F; Cassone A; Vecchiarelli A Infect Immun; 2007 Nov; 75(11):5085-94. PubMed ID: 17606600 [TBL] [Abstract][Full Text] [Related]
13. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. Kozel TR; Gotschlich EC J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244 [TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance. Zaragoza O; Casadevall A Cell Microbiol; 2006 Dec; 8(12):1862-76. PubMed ID: 16824038 [TBL] [Abstract][Full Text] [Related]
15. Induction of interleukin-6 mRNA in rat alveolar macrophages by in vitro exposure to both Cryptococcus neoformans and anti-C. neoformans antiserum. Li RK; Mitchell TG J Med Vet Mycol; 1997; 35(5):327-34. PubMed ID: 9402525 [TBL] [Abstract][Full Text] [Related]
16. CR3-dependent phagocytosis by murine macrophages: different cytokines regulate ingestion of a defined CR3 ligand and complement-opsonized Cryptococcus neoformans. Cross CE; Collins HL; Bancroft GJ Immunology; 1997 Jun; 91(2):289-96. PubMed ID: 9227330 [TBL] [Abstract][Full Text] [Related]
17. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. Chaturvedi V; Wong B; Newman SL J Immunol; 1996 May; 156(10):3836-40. PubMed ID: 8621921 [TBL] [Abstract][Full Text] [Related]
18. Cryptococcus neoformans is resistant to surfactant protein A mediated host defense mechanisms. Giles SS; Zaas AK; Reidy MF; Perfect JR; Wright JR PLoS One; 2007 Dec; 2(12):e1370. PubMed ID: 18159253 [TBL] [Abstract][Full Text] [Related]
19. Macrophage-mediated fungistasis in vitro: requirements for intracellular and extracellular cytotoxicity. Granger DL; Perfect JR; Durack DT J Immunol; 1986 Jan; 136(2):672-80. PubMed ID: 3510251 [TBL] [Abstract][Full Text] [Related]
20. Immunology of infection caused by Cryptococcus neoformans. Wormley FL; Perfect JR Methods Mol Med; 2005; 118():193-8. PubMed ID: 15888944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]